Engelbertsen et al. have shown in a hypercholesterolaemic mouse model lacking adaptive immunity that treatment with IL-2/anti-IL2 complexes expands CD25+ ILCs leading to decreased plaque size, a phenomenon that was accompanied by reduced cholesterol levels in serum and eosinophilia [26]. This evidence concerns the gene IL2 and Increased total eosinophil count.